Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals Limited has announced an investor conference call to discuss the BLA filing update for its renal cancer imaging agent, TLX250-CDx. The call is scheduled for August 1, 2024, and aims to address Telix’s developments in diagnostic and therapeutic radiopharmaceuticals. Interested parties can register online to join the conference call and webcast.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.